Professional · Issue 4 · 2026-10-15
CFTR Modulators Associated with Improved Mental Health and Sleep in Children with CF and Their Caregivers Over 18 Months
Editorially reviewed research summaries, context, and limitations.
Hande Yetişgin, Işıl Bilgiç, Meltem Kürtül Çakar, et al.
Summary: This prospective observational study from Turkey followed 24 children with cystic fibrosis receiving CFTR modulator therapy and their parents over 18 months, measuring mental health, sleep quality, and quality of life at baseline and follow-up. Statistically significant improvements were observed in child anxiety, depression, and daytime sleepiness scores, as well as in parental depression, anxiety, caregiver burden, and overall quality of life. CFQ-R scores improved in physical, social, and respiratory domains for both patients and parent proxies.
Why it matters: The psychological burden of CF on patients and families is substantial and historically underappreciated relative to pulmonary outcomes. If CFTR modulators — already known to improve lung function and nutritional status — also meaningfully reduce anxiety, depression, and caregiver burden, the case for early and sustained access to these therapies becomes even stronger. This study adds longitudinal data to a literature dominated by cross-sectional observations, which is a meaningful methodological step forward, even if the sample is small.
Expert perspective: The findings are directionally plausible and clinically interesting, but several limitations prevent strong causal conclusions. Most fundamentally, the study lacks a control group. With only 24 participants — drawn from a single center in Turkey and representing a continuation of a prior cross-sectional study — it is impossible to distinguish the effects of modulator therapy from natural disease trajectory, regression to the mean, the passage of time, or the psychosocial benefits of being enrolled in an attentive clinical study. The 18-month follow-up is a genuine strength relative to most prior work, and the use of validated instruments (CDI, SCARED, BDI, BAI, ZBI, WHOQOL-BREF, CFQ-R) is appropriate. However, statistical significance across multiple endpoints in a sample this small warrants caution; with n=24, the study is underpowered to reliably estimate effect sizes, and multiple comparisons increase the risk of spurious findings. Eighteen months of modulator therapy inevitably produces respiratory and nutritional improvements, making it exceedingly difficult to isolate a direct psychosocial effect of the drug from indirect benefits mediated through better physical health. The generalizability of findings to populations with different modulator access patterns, healthcare contexts, or CF mutation distributions is uncertain. Despite these limitations, this is a useful piece of incremental evidence suggesting that the benefits of CFTR modulators likely extend beyond forced expiratory volume. Larger, controlled, multicenter studies — ideally incorporating diverse CF populations and stratifying by modulator type — are needed before firm conclusions can be drawn.
Relevance: Cystic Fibrosis
Source: https://pubmed.ncbi.nlm.nih.gov/42576010/
---